Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259607 | 0.87 | RAB9A (0.55) | RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8267253 | 0.83 | RAB9A (0.71) | RAB9ASMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL22287932 | 0.81 | RAB9A (0.54) | RAB9ASMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL960306 | 0.81 | MAPT (0.62) | RAB9ASMN1; SMN2MAPTBRD4GAA | |
| SCHEMBL12112024 | 0.79 | AURKA (0.54) | RAB9ASMN1; SMN2BRD4KDM4ENPC1 | |
| SCHEMBL874228 | 0.78 | GUSB (0.73) | RAB9ANPC1 | |
| SCHEMBL29784145 | 0.78 | GUSB (0.73) | RAB9ANPC1 | |
| SCHEMBL22287887 | 0.78 | SPR (0.69) | RAB9ASMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL29397961 | 0.78 | SPR (0.69) | RAB9ASMN1; SMN2MAPTKDM4ENPC1 | |
| SCHEMBL17786385 | 0.77 | BRD4 (0.53) | RAB9ASMN1; SMN2BRD4KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522614-B2 | Topical phosphoinositide 3-kinase inhibitors | VENTHERA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230416269-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | COA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11661429-B2 | Topical phosphoinositide 3-kinase inhibitors | VENTHERA, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-114072144-A | External phosphoinositide 3-kinase inhibitors | 维瑟拉有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3920911-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Venthera, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163525-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | VENTHERA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163525-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | VENTHERA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247816-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | NAVIRE PHARMA, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200247816-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | NAVIRE PHARMA, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-2035431-B1 | THIENO[3,2-D]PYRIMIDINES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE FOR THE TREATMENT OF CANCER DISEASES | HOFFMANN LA ROCHE (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247816-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3C3, PIK3CA, PIK3R1 | RAB9A 1294/4885SMN1; SMN2 4284/4885MAPT 4326/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | RAB9A 613/4885SMN1; SMN2 4764/4885MAPT 3923/4885 |
| US-11661429-B2 | Topical phosphoinositide 3-kinase inhibitors | PIK3C3, PIK3CA, PIK3R1 | RAB9A 1294/4885SMN1; SMN2 4284/4885MAPT 4326/4885 |
| US-20230416269-A1 | TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3C3, PIK3CA, PIK3R1 | RAB9A 1294/4885SMN1; SMN2 4284/4885MAPT 4326/4885 |
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | RAB9A 637/4885SMN1; SMN2 1214/4885MAPT 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.